Refine
Year of publication
- 2013 (285) (remove)
Document Type
- Article (242)
- Conference Proceeding (13)
- Part of Periodical (12)
- Doctoral Thesis (9)
- Contribution to a Periodical (6)
- Book (1)
- Part of a Book (1)
- Periodical (1)
Is part of the Bibliography
- no (285)
Keywords
- Video (19)
- Capsule endoscopy (12)
- Small bowel (10)
- Endoscopy (7)
- Balloon enteroscopy (6)
- Enteroscopy (6)
- Endoscopic retrograde cholangiopancreatography (4)
- Apoptosis (3)
- IAP proteins (3)
- Smac (3)
- epigenetics (3)
- Atrial fibrillation (2)
- Bile duct stone (2)
- Blog (2)
- Breast cancer (2)
- CBA (2)
- COPD (2)
- Cholangiography (2)
- Cholangiopancreatography (2)
- Colonoscopy (2)
- Colorectal cancer (2)
- Double-balloon enteroscopy (2)
- Endoscopic retrograde (2)
- Enterscopy (2)
- Extended donor criteria (2)
- Hemorrhage (2)
- Herb induced liver injury (2)
- IL-6 (2)
- KGF (2)
- Lymphectasia (2)
- Migration (2)
- PDGFRβ (2)
- ROS (2)
- Rhabdomyosarcoma (2)
- SD-OCT (2)
- Sestrin 2 (2)
- Social Media (2)
- Standard endoscopy (2)
- Stroke (2)
- Thrombolysis (2)
- VEGF (2)
- Web 2.0 (2)
- apoptosis (2)
- cardiac (2)
- cell death (2)
- glioblastoma (2)
- immunotherapy (2)
- leukemia (2)
- radiotherapy (2)
- signal transduction (2)
- therapy (2)
- ALL (1)
- AML (1)
- Actin (1)
- Adenocarcinoma (1)
- Adhesion (1)
- Adolescence (1)
- Airways (1)
- Allergy (1)
- Angiectasia (1)
- Angiodysplasia (1)
- Antarctic marine sponges (1)
- Antibiotic generic drugs (1)
- Anticoagulation (1)
- Antifungal agents (1)
- Antineoplastic agents (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Aortic debranching (1)
- Aortic dissection (1)
- Aromatase inhibitors (1)
- Arteriovenous malformation (1)
- Aspergillosis (1)
- Assessment (1)
- Asthma (1)
- Auric nanoparticles (1)
- Autism spectrum disorder (1)
- B-cell (1)
- B16 cells (1)
- BCL2 (1)
- BCR-ABL (1)
- BRVO (1)
- Ballet (1)
- Ballon-assisted enteroscopy (1)
- Bcl-2 (1)
- Benign disorder (1)
- Bevacizumab (1)
- Billroth II gastroenterostomy (1)
- Billroth papillotome (1)
- Billroth’s operation-II (1)
- Blood-brain barrier (1)
- Bortezomib (1)
- Brain (1)
- Brain development (1)
- Brain repair (1)
- C1-inhibitor deficiency (1)
- CIOMS (1)
- CRVO (1)
- CXCL12 (1)
- CXCR4 (1)
- Cancer (1)
- Cancer stem cells (1)
- Candida (1)
- Capecitabine (1)
- Capsule endoscopy, video (1)
- Cardiac surgery (1)
- Castleman’s disease (1)
- Catheter ablation (1)
- Celiac disease (1)
- Cell Death (1)
- Cell Signaling (1)
- Cell Surface Receptor (1)
- Cellular Immune Response (1)
- Cerasorb (1)
- Cerebral Vasospasm (1)
- Chemoradiotherapy (1)
- Chronic illness (1)
- Chronic obstructive airway disease (1)
- Clip (1)
- Cohort study (1)
- Communication (1)
- Comparative study (1)
- Core needle biopsy (1)
- Coronary artery disease (CAD) (1)
- Crohn’s disease (1)
- Cryoablation (1)
- Cyanoacrylate (1)
- Cytochrome P450 (1)
- Cytokine (1)
- Cytotoxicity (1)
- DNA Adducts (1)
- DR5 (1)
- Dancer (1)
- Delayed Cerebral Ischemia (1)
- Dentin adhesives (1)
- Device (1)
- Diabetic nephropathy (1)
- Dieulafoy’s lesion (1)
- Digestive system (1)
- Dilated cardiomyopathy (1)
- Disease management (1)
- Docetaxel (1)
- Double balloon enteroscopy (1)
- Doubling time (1)
- Drug Therapy (1)
- Drug hepatotoxicity (1)
- Drug induced liver injury (1)
- Duodenum (1)
- EEG (1)
- EWS/Fli1 (1)
- Ectopic bone formation (1)
- Ectopic varices (1)
- Effectivity (1)
- Elderly (1)
- Ellipticine (1)
- Endomicroscopy (1)
- Endoscopic papillotomy (1)
- Endoscopic retrograde cholangiography (1)
- Endoscopic sphincterotomy (1)
- Endoscopic treatment (1)
- Endoscopic ultrasound (1)
- Esophagogastric (1)
- Europe (1)
- Ewing sarcoma (1)
- Exemestane (1)
- FAP (1)
- FTY720 (1)
- Facet joint osteoarthritis (1)
- Fast-track (1)
- Female (1)
- Fever (1)
- Fibrinolytic (1)
- Fingolimod (1)
- G-CSF (1)
- Gastric adenoma (1)
- Gastric cancer (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gene polymorphism (1)
- Generic drugs (1)
- German (1)
- Giant lymph node hyperplasia (1)
- Glivec® (1)
- Glomerulonephritis (1)
- Gold (1)
- Graft function (1)
- Graft survival (1)
- Graz <2013> (1)
- HAE (1)
- HDACi (1)
- HIV therapy (1)
- HNPCC (1)
- HSPC (1)
- Heart (1)
- Hebbian plasticity (1)
- Hematologic malignancies (1)
- Hemobilia (1)
- Hepatitis C (1)
- Herbalife products (1)
- Hexavalent vaccine (1)
- Hormonal (1)
- Hydroxyapatite (1)
- IAPs (1)
- ICU (1)
- IMiD® (1)
- ISO (1)
- Identity (1)
- Immunology (1)
- In-vivo (1)
- Inflammatory bowel disease (1)
- Inflammatory fibroid polyp (1)
- Innate Immunity (1)
- Innate immunity (1)
- Integrin (1)
- Intestinal fistula (1)
- Intestinal metaplasia (1)
- Intestinal neoplasms (1)
- Invasive candidiasis (1)
- Ischemia (1)
- Ischemia-reperfusion injury (1)
- Kava (1)
- Kidney disease (1)
- Kommunikation (1)
- Kongress (1)
- L2 (1)
- Landmark (1)
- Langerhans cell histiocytosis (1)
- Liver biopsy (1)
- Liver histology (1)
- Liver injury (1)
- Liver transplantation (1)
- Lumbar stenosis (1)
- Lung (1)
- Lymphangiectasia (1)
- Lymphoepithelioma (1)
- Lymphoma (1)
- MACE (1)
- MCAO (1)
- MCP (1)
- MCP-1 (1)
- MEG (1)
- MLL (1)
- MTCL (1)
- MTT (1)
- Male (1)
- Marginal grafts (1)
- Medizinische Ausbildung (1)
- Mena/VASP (1)
- Metal clip (1)
- Metastatic (1)
- Mid-intestinal bleeding (1)
- Minimally invasive transforaminal interbody fusion (1)
- Moderating factors (1)
- Multiple trauma (1)
- Musical rhythm (1)
- Mycoses (1)
- NF-κB (1)
- NK Receptor (1)
- NK cell (1)
- NS3-4A protease inhibitor (1)
- NS5B polymerase inhibitor (1)
- NanoBone (1)
- Nanocrystalline (1)
- Natural Killer (NK) Cell (1)
- Neoadjuvant radiochemotherapy (1)
- Neoadjuvant treatment (1)
- Neural function (1)
- Neural stem cells (1)
- Neuroendocrine tumor (1)
- Neurogenesis (1)
- Neurotransmitter (1)
- New Developments (1)
- Non-Hodgkin lymphoma (1)
- Occupational disease (1)
- Occupational exposure (1)
- Occupational health (1)
- Oesophagogastric cancer oxaliplatin (1)
- Off-pump surgery (1)
- Oncolytic virus (1)
- Oncotargets (1)
- Online-Magazin (1)
- Online-Magazine (1)
- Organ allocation (1)
- Organ rinse (1)
- Organ shortage (1)
- Osteoinduction (1)
- Osteoporosis (1)
- Outcome (1)
- Over-the-scope clip (1)
- Oxaliplatin (1)
- PAX3/FOXO1 (1)
- PET (1)
- Pancreas transplantation (1)
- Paracetamol (1)
- Paraneoplastic syndrome (1)
- Pathologic complete response (1)
- Pelargonium sidoides (1)
- Percutaneous ultrasound (1)
- Peroxidase (1)
- Personality disorder (1)
- Peutz–Jeghers syndrome (1)
- Pharmacodynamic (1)
- Physical therapist (1)
- Planning target volume (1)
- Platelets (1)
- Pneumococcal conjugate vaccine (1)
- Polyposis syndrome (1)
- Postoperative anatomy (1)
- Preoperative radiochemotherapy (1)
- Prophylaxis (1)
- Protein Expression (1)
- Psychopathology (1)
- Pulmonary failure (1)
- Pulmonary veins (1)
- Qualitative research (1)
- RAD001 (1)
- RIP1 (1)
- RNA interference (RNAi) (1)
- RUNX1/ETO (1)
- Radiation induced diarrhoea (1)
- Radiotherapy (1)
- Rare disease (1)
- Readmission (1)
- Rectal cancer (1)
- Rejection (1)
- Restenosis (1)
- S1P1 receptor (1)
- SERS (1)
- SOCS (1)
- Selenium administration in gynecologic radiation oncology (1)
- Self-expandable metal stents (1)
- Self-expandable metal stents complications (1)
- Self-management support (1)
- Signaling (1)
- Small-bowel endoscopy (1)
- Social skills training (1)
- Spectrin (1)
- Sphingolipid (1)
- Sphingosine 1-phosphate (1)
- Spondylolisthesis (1)
- Stentoplasty (1)
- Study protocol (1)
- Subacute cerebellar degeneration (1)
- Subarachnoid Hemorrhage (1)
- Supraventricular arrhythmias (1)
- Syk Kinase (1)
- T cell (1)
- T-cell homeostasis (1)
- T-cell niche (1)
- TEM (1)
- TEVAR (1)
- TKI (1)
- TRAIL (1)
- Tacrolimus (1)
- Tamoxifen (1)
- Temozolomide (1)
- Terminal ileitis (1)
- Thalidomide (1)
- Thoracic trauma (1)
- Thyroid Cancer Cells (1)
- Toll-like receptor (TLR) 6 (1)
- Tonsil (1)
- Toxicology (1)
- Toxins (1)
- Traumatic injury (1)
- Treatment (1)
- Tumor obstruction (1)
- Tumor subtype (1)
- Turkish (1)
- Ultrasonography (1)
- VEGF receptors (1)
- VIP (1)
- VPAC1 (1)
- Variceal bleeding (1)
- Vertebral augmentation (1)
- Vertebral body stenting (1)
- Vertebral fracture (1)
- Virotherapy (1)
- Vitreous samples (1)
- Western Blotting (1)
- Wilms tumor (1)
- XIAP (1)
- YB-1 (1)
- acetylcholine receptors (1)
- acetylcholinesterase inhibition (1)
- acute leukemia (1)
- acute lymphoblastic leukaemia (1)
- acute myeloid leukaemia (1)
- aesthetics (1)
- ageing (1)
- aging (1)
- air pouch (1)
- all-ceramic (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alpha peak (1)
- antibacterial activity (1)
- antifungal agents (1)
- antifungal management (1)
- antifungal prophylaxis (1)
- astrocyte (1)
- astrocytes (1)
- atherosclerosis (1)
- attention (1)
- barriers to implementation (1)
- biocompatibility (1)
- bone morphogenetic protein-2 (1)
- bone substitute material (1)
- bortezomib (1)
- brain injury (1)
- cIAP1 BIR (1)
- cancer (1)
- cardiovascular (1)
- cardiovascular disease (1)
- chemotherapy (1)
- childhood cancer (1)
- chromosomal translocations (1)
- chronic care (1)
- cigarette (1)
- clinical research (1)
- clinical study (1)
- clinical trials (1)
- cochlear implant (1)
- cognitive fluency (1)
- consciousness (1)
- corticomuscular coherence (CMC) (1)
- costs (1)
- crestal bone loss (1)
- critical periods (1)
- crowns (1)
- cytotoxicity (1)
- deconvolution (1)
- development (1)
- directly acting antiviral agents (1)
- distraction (1)
- dual task (1)
- emotion (1)
- endothelial (1)
- english (1)
- entorhinal cortex lesion (1)
- everolimus (1)
- exercise (1)
- expert review (1)
- fMRI (1)
- finger tapping (1)
- functional MRI (1)
- fungal infection (1)
- gamma (1)
- gastric (1)
- gastrointestinal (1)
- gene therapy (1)
- gland extracts (1)
- glutamate metabolism (1)
- granulocyte (1)
- growth factor (1)
- hand area (1)
- head and neck cancer (1)
- hematopoietic stem and progenitor cells (1)
- hemodialysis (1)
- hemolysis (1)
- hepatitis C virus (1)
- hereditary angioedema (1)
- hippocampal volume (1)
- homeostatic synaptic scaling (1)
- iPS (1)
- immune function (1)
- immunocytochemistry (1)
- immunology (1)
- implant (1)
- implant survival (1)
- inflammation (1)
- inhibition of DNA-binding (1)
- interferon-free (1)
- interleukin-10 (1)
- interleukin-22 (1)
- invasive fungal infection (1)
- kidney disease (1)
- lenalidomide (1)
- long-term survival (1)
- mTOR (1)
- magnetoencephalography (1)
- magnetoencephalography (MEG) (1)
- marginal bone loss (1)
- mature T-cell lymphoma (1)
- memory (1)
- metaplasticity (1)
- metastases (1)
- meter (1)
- miRNA (1)
- miRNA-17–92 (1)
- microRNA (1)
- migration (1)
- mild cognitive impairment (1)
- mitogen-activated protein kinase (1)
- mitomycin C (1)
- mobilization (1)
- monogenic disorders (1)
- motor control (1)
- motor task (1)
- nanoparticles (1)
- natural killer cell (1)
- necroptosis (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological diseases (1)
- neurooncology (1)
- neuropsychiatric disorders (1)
- next-generation sequencing (1)
- non-invasive brain stimulation (1)
- oligodendrocyte (1)
- organotypic slice cultures (1)
- oxidative stress (1)
- pain (1)
- peptide aptamer (PA) (1)
- perceptual organization (1)
- plasticity (1)
- poetry (1)
- posaconazole (1)
- potassium channels (1)
- pregnancy (1)
- pregnant (1)
- preprocedure prophylaxis (1)
- prevention (1)
- primary motor cortex (1)
- primary motor cortex (M1) (1)
- prognostic value (1)
- progranulin (1)
- prostate and breast cancer cell lines (1)
- prostate cancer (1)
- proteasome inhibitor (1)
- protein transduction (1)
- rat femur defect (1)
- receptor tyrosine kinase (1)
- resting state (1)
- rhyme (1)
- rhythmic aptitude (1)
- scaffolding proteins (1)
- schizophrenia (1)
- sciatic nerve injury (1)
- self-management support (1)
- senescence (1)
- signal transducer and activator of transcription (1)
- signal transducer and activator of transcription 5 (Stat5) (1)
- signaling (1)
- single-sided deafness (1)
- sleep (1)
- slowing (1)
- smoking (1)
- sodium channels (1)
- sonic hedgehog (1)
- speech rhythm (1)
- stem cell therapy (1)
- stem/progenitor cell expansion (1)
- structural plasticity (1)
- surgical procedures (1)
- survival rate (1)
- synchrony (1)
- terebridae venom (1)
- thalidomide (1)
- therapeutics (1)
- three point bending test (1)
- tobacco (1)
- tooth wear (1)
- toxicity (1)
- transcranial alternating current stimulation (tACS) (1)
- translocation partner genes (1)
- tricalcium phosphate (1)
- tumour (1)
- tumour-infiltrating lymphocytes (1)
- type I interferons (1)
- vascular (1)
- viral vectors (1)
- vitreous samples (1)
- yeast-two-hybrid (Y2H) (1)
- ß-tricalciumphosphate (1)
Institute
- Medizin (285) (remove)
Background: A number of scientific papers on yellow fever have been published but no broad scientometric analysis on the published research of yellow fever has been reported. The aim of the article based study was to provide an in-depth evaluation of the yellow fever field using large-scale data analysis and employment of bibliometric indicators of production and quantity.
Methods: Data were retrieved from the Web of Science database (WoS) and analyzed as part of the NewQis platform. Then data were extracted from each file, transferred to databases and visualized as diagrams. Partially by means of density-equalizing mapping makes the findings clear and emphasizes the output of the analysis.
Results: In the study period from 1900 to 2012 a total of 5,053 yellow fever-associated items were published by 79 countries. The United States (USA) having the highest publication rate at 42% (n = 751) followed by far from Brazil (n = 203), France (n = 149) and the United Kingdom (n = 113). The most productive journals are the "Public Health Reports", the "American Journal of Tropical Medicine and Hygiene" and the "Journal of Virology". The gender analysis showed an overall steady increase of female authorship from 1950 to 2011. Brazil is the only country of the five most productive countries with a higher proportion of female scientists.
Conclusions: The present data shows an increase in research productivity over the entire study period, in particular an increase of female scientists. Brazil shows a majority of female authors, a fact that is confirmed by other studies.
Background: Tobacco is a leading environmental factor in the initiation of respiratory diseases and causes chronic obstructive pulmonary disease (COPD). Suppressor of cytokine signaling (SOCS) family members are involved in the pathogenesis of many inflammatory diseases and SOCS-3 has been shown to play an important role in the regulation, onset and maintenance of airway allergic inflammation indicating that SOCS-3 displays a potential therapeutic target for anti-inflammatory respiratory drugs development. Since chronic obstructive pulmonary disease (COPD) is also characterized by inflammatory changes and airflow limitation, the present study assessed the transcriptional expression of SOCS-3 in COPD.
Methods: Real-time PCR was performed to assess quantitative changes in bronchial biopsies of COPD patients in comparison to unaffected controls.
Results: SOCS-3 was significantly down-regulated in COPD at the transcriptional level while SOCS-4 and SOCS-5 displayed no change.
Conclusions: It can be concluded that the presently observed inhibition of SOCS-3 mRNA expression may be related to the dysbalance of cytokine signaling observed in COPD.
Vasoactive intestinal polypeptide (VIP) is a putative neurotransmitter of the inhibitory non-adrenergic non-cholinergic nervous system and influences the mammalian airway function in various ways. Hence known for bronchodilatory, immunomodulatory and mucus secretion modulating effects by interacting with the VIP receptors VPAC1 and VPAC2, it is discussed to be a promising target for pharmaceutical intervention in common diseases such as COPD and bronchial asthma. Here we examined the expression and transcriptional regulation of VPAC1 in the lungs of allergic mice using an ovalbumin (OVA) -induced model of allergic asthma. Mice were sensitized to OVA and challenged with an OVA aerosol. In parallel a control group was sham sensitized with saline. VPAC1 expression was examined using RT-PCR and real time-PCR studies were performed to quantify gene transcription. VPAC1 mRNA expression was detected in all samples of OVA-sensitized and challenged animals and control tissues. Further realtime analysis did not show significant differences at the transcriptional level.
Although the present studies did not indicate a major transcriptional regulation of VPAC1 in states of allergic airway inflammation, immunomodulatory effects of VPAC1 might still be present due to regulations at the translational level.
Background: Interferon and ribavirin therapy for chronic hepatitis C virus (HCV) infection yields sustained virological response (SVR) rates of 50–80%. Several factors such as non-1 genotype, beneficial IL28B genetic variants, low baseline IP-10, and the functionality of HCV-specific T cells predict SVR. With the pending introduction of new therapies for HCV entailing very rapid clearance of plasma HCV RNA, the importance of baseline biomarkers likely will increase in order to tailor therapy. CD26 (DPPIV) truncates the chemokine IP-10 into a shorter antagonistic form, and this truncation of IP-10 has been suggested to influence treatment outcome in patients with chronic HCV infection patients. In addition, previous reports have shown CD26 to be a co-stimulator for T cells. The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells.
Methods: Baseline plasma from 153 genotype 1 and 58 genotype 2/3 infected patients enrolled in an international multicenter phase III trial (DITTO-HCV) and 36 genotype 1 infected patients participating in a Swedish trial (TTG1) were evaluated regarding baseline soluble CD26 (sCD26) and the functionality of HCV-specific CD8+ T cells.
Results: Genotype 1 infected patients achieving SVR in the DITTO (P = 0.002) and the TTG1 (P = 0.02) studies had lower pretreatment sCD26 concentrations compared with non-SVR patients. Sixty-five percent of patients with sCD26 concentrations below 600 ng/mL achieved SVR compared with 39% of the patients with sCD26 exceeding 600 ng/mL (P = 0.01). Patients with sCD26 concentrations below 600 ng/mL had significantly higher frequencies of HCV-specific CD8+ T cells (P = 0.02).
Conclusions: Low baseline systemic concentrations of sCD26 predict favorable treatment outcome in chronic HCV infection and may be associated with higher blood counts of HCV-specific CD8+ T cells.
Oral presentation: 23rd World Congress of the World Society of Cardio-Thoracic Surgeons. Split, Croatia. 12-15 September 2013.
Background: In the past, questions have been raised, whether an open flexible annuloplasty band can reliably prevent recurrent mitral valve regurgitation. The purpose of this study was to evaluate the durability of mitral valve repair at midterm, using the Cosgrove-Edwards annuloplasty band in a homogenic patient cohort.
Methods: From January 2004 to December 2007, 157 consecutive patients with degenerative mitral valve disease were included in the study. All had quadrangular resection of a P2 prolapse and annuloplasty with a Cosgrove-Edwards annuloplasty band. Clinical and echocardiography follow-up was complete.
Results: There was no intraoperative or 30 day mortality. After a mean follow-up of 5.0 ± 1.9 years, survival was 94.3%. At midterm, freedom from reoperations was 98.9%, freedom from thromboembolism was 97.5% and freedom from endocarditis was 99.4%. Echocardiography follow-up showed recurrent mitral valve regurgitation higher than grade 2 in two patients. Mean ejection fraction was 60.3 ± 10.2%, left atrial diameter was 42 ± 7 mm, mean gradient was 3.2 ± 1.4 mmHg, effective orifice area was 3.3 ± 1.3cm², mitral leaflet coaptation length was 7.5 ± 1.9 mm and mitral leaflet tethering height was 6.2 ± 2.3 mm.
Conclusion: Mitral valve repair using the Cosgrove annuloplasty band for degenerative mitral valve disease provides an effective and durable form of reconstruction.
Persistent infections with hepatitis C virus (HCV) may result in life-threatening liver disease, including cirrhosis and cancer, and impose an important burden on human health. Understanding how the virus is capable of achieving persistence in the majority of those infected is thus an important goal. Although HCV has evolved multiple mechanisms to disrupt and block cellular signaling pathways involved in the induction of interferon (IFN) responses, IFN-stimulated gene (ISG) expression is typically prominent in the HCV-infected liver. Here, we show that Toll-like receptor 3 (TLR3) expressed within uninfected hepatocytes is capable of sensing infection in adjacent cells, initiating a local antiviral response that partially restricts HCV replication. We demonstrate that this is dependent upon the expression of class A scavenger receptor type 1 (MSR1). MSR1 binds extracellular dsRNA, mediating its endocytosis and transport toward the endosome where it is engaged by TLR3, thereby triggering IFN responses in both infected and uninfected cells. RNAi-mediated knockdown of MSR1 expression blocks TLR3 sensing of HCV in infected hepatocyte cultures, leading to increased cellular permissiveness to virus infection. Exogenous expression of Myc-MSR1 restores TLR3 signaling in MSR1-depleted cells with subsequent induction of an antiviral state. A series of conserved basic residues within the carboxy-terminus of the collagen superfamily domain of MSR1 are required for binding and transport of dsRNA, and likely facilitate acidification-dependent release of dsRNA at the site of TLR3 expression in the endosome. Our findings reveal MSR1 to be a critical component of a TLR3-mediated pattern recognition receptor response that exerts an antiviral state in both infected and uninfected hepatocytes, thereby limiting the impact of HCV proteins that disrupt IFN signaling in infected cells and restricting the spread of HCV within the liver.
Background: Whereas it is well established that various soluble biomarkers can predict level of liver fibrosis, their ability to predict liver-related clinical outcomes is less clearly established, in particular among HIV/viral hepatitis co-infected persons. We investigated plasma hyaluronic acid’s (HA) ability to predict risk of liver-related events (LRE; hepatic coma or liver-related death) in the EuroSIDA study.
Methods: Patients included were positive for anti-HCV and/or HBsAg with at least one available plasma sample. The earliest collected plasma sample was tested for HA (normal range 0–75 ng/mL) and levels were associated with risk of LRE. Change in HA per year of follow-up was estimated after measuring HA levels in latest sample before the LRE for those experiencing this outcome (cases) and in a random selection of one sixth of the remaining patients (controls).
Results: During a median of 8.2 years of follow-up, 84/1252 (6.7%) patients developed a LRE. Baseline median (IQR) HA in those without and with a LRE was 31.8 (17.2–62.6) and 221.6 ng/mL (74.9–611.3), respectively (p<0.0001). After adjustment, HA levels predicted risk of contracting a LRE; incidence rate ratios for HA levels 75–250 or ≥250 vs. <75 ng/mL were 5.22 (95% CI 2.86–9.26, p<0.0007) and 28.22 (95% CI 14.95–46.00, p<0.0001), respectively. Median HA levels increased substantially prior to developing a LRE (107.6 ng/mL, IQR 0.8 to 251.1), but remained stable for controls (1.0 ng/mL, IQR –5.1 to 8.2), (p<0.0001 comparing cases and controls), and greater increases predicted risk of a LRE in adjusted models (p<0.001).
Conclusions: An elevated level of plasma HA, particularly if the level further increases over time, substantially increases the risk of contracting LRE over the next five years. HA is an inexpensive, standardized and non-invasive supplement to other methods aimed at identifying HIV/viral hepatitis co-infected patients at risk of hepatic complications.